NeuroSense Therapeutics Ltd., a foreign private issuer, reported to the U.S. Securities and Exchange Commission (SEC) that on August 6, 2024, it entered into a securities purchase agreement with certain investors, including senior management and existing shareholders. The private placement offering was conducted at a 10% premium to the closing price on the Nasdaq Capital Market on the agreement date. The company agreed to sell 800,000 ordinary shares and warrants to purchase an additional 800,000 shares at $0.75 each. The private placement is expected to close during the week of August 12, 2024, subject to customary closing conditions. The warrants are immediately exercisable upon issuance with a 5-year term and an exercise price of $0.75 per share. They may be exercised on a cashless basis if no effective...Show More

NeuroSense Therapeutics Ltd., a foreign private issuer, reported to the U.S. Securities and Exchange Commission (SEC) that on August 6, 2024, it entered into a securities purchase agreement with certain investors, including senior management and existing shareholders. The private placement offering was conducted at a 10% premium to the closing price on the Nasdaq Capital Market on the agreement date. The company agreed to sell 800,000 ordinary shares and warrants to purchase an additional 800,000 shares at $0.75 each. The private placement is expected to close during the week of August 12, 2024, subject to customary closing conditions. The warrants are immediately exercisable upon issuance with a 5-year term and an exercise price of $0.75 per share. They may be exercised on a cashless basis if no effective registration statement is available. The proceeds from the private placement are intended for general corporate and working capital purposes. The offering is made in reliance on an exemption from registration under the Securities Act of 1933, as amended, and is not an offer to sell or a solicitation of an offer to buy in any jurisdiction where such would be unlawful. This report includes forward-looking statements subject to risks and uncertainties, and the company does not undertake to update such statements.